Mayne Pharma Group (ASX:MYX) EV-to-EBIT : -3.28 (As of May. 04, 2024)

View and export this data going back to 2007. Start your Free Trial

What is Mayne Pharma Group EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Mayne Pharma Group's Enterprise Value is A$508.8 Mil. Mayne Pharma Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-155.2 Mil. Therefore, Mayne Pharma Group's EV-to-EBIT for today is -3.28.

The historical rank and industry rank for Mayne Pharma Group's EV-to-EBIT or its related term are showing as below:

ASX:MYX' s EV-to-EBIT Range Over the Past 10 Years
Min: -14.65 Med: -0.89 Max: 272.04
Current: -3.29

During the past 13 years, the highest EV-to-EBIT of Mayne Pharma Group was 272.04. The lowest was -14.65. And the median was -0.89.

ASX:MYX's EV-to-EBIT is ranked worse than
100% of 667 companies
in the Drug Manufacturers industry
Industry Median: 17.86 vs ASX:MYX: -3.29

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Mayne Pharma Group's Enterprise Value for the quarter that ended in Dec. 2023 was A$381.4 Mil. Mayne Pharma Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-155.2 Mil. Mayne Pharma Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -40.69%.

Mayne Pharma Group EV-to-EBIT Historical Data

The historical data trend for Mayne Pharma Group's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mayne Pharma Group EV-to-EBIT Chart

Mayne Pharma Group Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

EV-to-EBIT

Get a 7-Day Free Trial

-3.25

-8.74

-3.53

-4.04

-0.81

Mayne Pharma Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															-	-4.04	-	-0.81	-

Competitive Comparison of Mayne Pharma Group's EV-to-EBIT

For the Drug Manufacturers - General subindustry, Mayne Pharma Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mayne Pharma Group's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mayne Pharma Group's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Mayne Pharma Group's EV-to-EBIT falls into.

Mayne Pharma Group EV-to-EBIT Calculation

Mayne Pharma Group's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	508.762	/	-155.193
	=	-3.28

Mayne Pharma Group's current Enterprise Value is A$508.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Mayne Pharma Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-155.2 Mil.

Mayne Pharma Group (ASX:MYX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Mayne Pharma Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-155.193	/	381.42567
	=	-40.69 %

Mayne Pharma Group's Enterprise Value for the quarter that ended in Dec. 2023 was A$381.4 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Mayne Pharma Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-155.2 Mil.

Mayne Pharma Group EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Mayne Pharma Group's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Mayne Pharma Group (ASX:MYX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mayne Pharma Group Ltd (ASX:MYX) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

MAYNF:USA HG6:Germany

Address

1538 Main North Road, Salisbury South, Salisbury, SA, AUS, 5106

Website

http://www.maynepharma.com

Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Branded Products (BPD) and Portfolio Products Division (PPD). The Portfolio Products Division distributes dermatology products (branded and generic) in the US on a portfolio basis, The Branded Products Division distributes branded women's health products in the US. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.